Harvard Bioscience (HBIO) Other Accumulated Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Other Accumulated Expenses data on file, last reported at $14.9 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 896.66% year-over-year to $14.9 million in Q1 2026; TTM through Mar 2026 was $14.9 million, a 896.66% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, down 84.85% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $14.9 million, up from $1.4 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for HBIO reached as high as $14.9 million in Q1 2026 and fell as low as $736000.0 in Q2 2024.
• Historically, Other Accumulated Expenses has averaged $5.4 million across 5 years, with a median of $1.7 million in 2022.
• Across the five-year window, Other Accumulated Expenses slumped 91.86% in 2024 and surged 896.66% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $7.5 million in 2022, then soared by 41.88% to $10.6 million in 2023, then declined by 11.41% to $9.4 million in 2024, then tumbled by 84.85% to $1.4 million in 2025, then jumped by 946.32% to $14.9 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $14.9 million in Q1 2026, $1.4 million in Q4 2025, and $1.6 million in Q3 2025.